GAO Drug Safety Report Could Reignite Interest In FDA Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Grassley argues that the report, which calls for improvements to FDA’s postmarket drug safety practices, supports reform measures proposed in the FDA Safety Act.